Page last updated: 2024-08-24

telmisartan and Fatty Liver

telmisartan has been researched along with Fatty Liver in 14 studies

Research

Studies (14)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (57.14)	29.6817
2010's	6 (42.86)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cynis, H; Demuth, HU; Fujii, M; Haegele, M; Heiser, U; Hoffmann, T; Kehlen, A; Schilling, S; Shibazaki, Y; Yoneyama, H	1
Bochar, OM	1
Enjoji, M; Higuchi, N; Kato, M; Kohjima, M; Kotoh, K; Nakamuta, M; Nakashima, M	1
Georgescu, EF	1
Burgueño, AL; Carabelli, J; Pirola, CJ; Rosselli, MS; Schuman, M; Sookoian, S	1
Georgescu, EF; Ionescu, R; Mogoanta, L; Niculescu, M; Vancica, L	1
Kanayama, M; Kawai, K; Kudo, H; Mann, DA; Morita, S; Nakayama, Y; Oya, T; Sasahara, M; Sugiyama, T; Takahara, T; Yata, Y	1
Chayama, K; Hyogo, H; Kanno, K; Nabeshima, Y; Tazuma, S	1
Ebihara, K; Kusakabe, T; Kuwahara, K; Li, Y; Murray, M; Nakao, K; Naowaboot, J; Rong, X; Zhao, M	1
Kiomy Osako, M; Minobe, N; Miyake, T; Morishita, R; Moritani, T; Nakagami, F; Nakagami, H; Shimamura, M; Shimizu, H; Shimosato, T; Takeya, Y	1
Fujisawa, K; Kuwashiro, S; Matsumoto, T; Nishina, H; Oishi, T; Sakaida, I; Terai, S	1
Aso, K; Haneda, M; Kanamori, H; Makino, Y; Nakade, Y; Nakao, H; Ohashi, T; Okada, M; Sato, K; Tamaki, Y; Yamauchi, T; Yokohama, S; Yoneda, M	1
Kazdová, L; Kurtz, TW; Ogihara, T; Pravenec, M; Qi, NR; Sugimoto, K	1
Fujita, K; Inamori, M; Iwasaki, T; Kirikoshi, H; Maeyama, S; Mawatari, H; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Terauchi, Y; Wada, K; Yoneda, M	1

Reviews

1 review(s) available for telmisartan and Fatty Liver

Article	Year
Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option? Advances in therapy, 2008, Volume: 25, Issue:11 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Fatty Liver; Humans; Insulin Resistance; Losartan; Metabolic Syndrome; Renin-Angiotensin System; Telmisartan; Tetrazoles	2008

Trials

3 trial(s) available for telmisartan and Fatty Liver

Article	Year
Combined effect of appointment telmisartan and atorvastatin on hemodynamic indicators and the indicators of lipid profile in patients with arterial hypertension combined with obesity and steatohepatitis. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2014, Volume: 67, Issue:2 Pt 2 Topics: Acetamides; Adipokines; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Benzoates; Breath Tests; Cholesterol, LDL; Drug Therapy, Combination; Fatty Liver; Female; Hemodynamics; Heptanoic Acids; Humans; Hypertension; Lipids; Male; Middle Aged; Obesity; Pyrroles; Telmisartan; Triglycerides	2014
Therapeutic effect of ARBs on insulin resistance and liver injury in patients with NAFLD and chronic hepatitis C: a pilot study. International journal of molecular medicine, 2008, Volume: 22, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Benzimidazoles; Benzoates; Fatty Liver; Female; Hepatitis C, Chronic; Homeostasis; Humans; Hypertension; Imidazoles; Incidence; Insulin Resistance; Japan; Male; Middle Aged; Pilot Projects; Telmisartan; Tetrazoles	2008
Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World journal of gastroenterology, 2009, Feb-28, Volume: 15, Issue:8 Topics: Alanine Transaminase; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Aspartate Aminotransferases; Benzimidazoles; Benzoates; Blood Pressure; Fatty Liver; Female; Humans; Hypertension; Liver Function Tests; Male; Middle Aged; Patient Selection; Telmisartan; Tetrazoles; Valine; Valsartan	2009

Other Studies

10 other study(ies) available for telmisartan and Fatty Liver

Article	Year
Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. International journal of experimental pathology, 2013, Volume: 94, Issue:3 Topics: Aminoacyltransferases; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Cell Line, Tumor; Chemokine CCL2; Disease Models, Animal; Enzyme Inhibitors; Fatty Liver; Hepatitis; Human Umbilical Vein Endothelial Cells; Humans; Leukemia, Monocytic, Acute; Macrophages; Mice; Mice, Inbred C57BL; Monocytes; Non-alcoholic Fatty Liver Disease; Telmisartan	2013
Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model. Atherosclerosis, 2009, Volume: 206, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fats; Disease Models, Animal; Fatty Liver; Liver; Losartan; Male; Phosphoenolpyruvate Carboxykinase (GTP); Plasminogen Activator Inhibitor 1; PPAR alpha; Rats; Rats, Sprague-Dawley; Telmisartan; Triglycerides	2009
Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:7 Topics: Adipocytes; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Cell Line; Cell Size; Chemokine CCL2; Choline Deficiency; Collagen Type I; Disease Models, Animal; Disease Progression; Drinking; Eating; Fatty Liver; Intra-Abdominal Fat; Liver; Liver Cirrhosis; Macrophages; Male; Methionine; Mice; Mice, Inbred C57BL; Organ Size; Oxidative Stress; Receptors, CCR2; RNA, Messenger; Telmisartan; Transforming Growth Factor beta1; Triglycerides	2009
Deletion of angiotensin II type I receptor reduces hepatic steatosis. Journal of hepatology, 2009, Volume: 50, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Benzimidazoles; Benzoates; Cell Line; DNA Primers; Fatty Liver; Gene Silencing; Humans; Lipid Metabolism; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; PPAR alpha; PPAR gamma; Receptor, Angiotensin, Type 1; RNA, Messenger; RNA, Small Interfering; Telmisartan	2009
Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice. Diabetologia, 2010, Volume: 53, Issue:8 Topics: Adipocytes; Adipose Tissue, White; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Cell Size; Diet, High-Fat; Fatty Liver; Insulin; Insulin Resistance; Leptin; Lipids; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Obesity, Abdominal; Organ Size; PPAR gamma; Receptor, Angiotensin, Type 1; Telmisartan; Triglycerides	2010
Prevention and regression of non-alcoholic steatohepatitis (NASH) in a rat model by metabosartan, telmisartan. International journal of molecular medicine, 2010, Volume: 26, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Fatty Liver; Hepatocyte Growth Factor; Liver; PPAR gamma; Rats; Rats, Wistar; Telmisartan	2010
Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation. Cell and tissue research, 2011, Volume: 344, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Carnitine O-Palmitoyltransferase; Cell Movement; Disease Models, Animal; Fats; Fatty Liver; Gene Expression; Humans; Macrophages; Non-alcoholic Fatty Liver Disease; Oryzias; Oxidative Stress; PPAR gamma; Telmisartan; Weight Gain	2011
Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. Journal of gastroenterology, 2013, Volume: 48, Issue:4 Topics: Amino Acids; Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Benzimidazoles; Benzoates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Choline Deficiency; Diet; Drug Evaluation, Preclinical; Fatty Liver; Gene Expression Regulation; Hypoxia-Inducible Factor 1, alpha Subunit; Liver; Liver Cirrhosis; Liver Neoplasms, Experimental; Male; Neovascularization, Pathologic; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Telmisartan; Vascular Endothelial Growth Factor A	2013
Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension (Dallas, Tex. : 1979), 2006, Volume: 47, Issue:5 Topics: Adipocytes; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cell Count; Cell Size; Energy Metabolism; Fatty Liver; Gene Expression; Male; Mitochondria; Rats; Rats, Sprague-Dawley; Telmisartan; Tetrazoles; Valine; Valsartan; Weight Gain	2006
Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Digestive diseases and sciences, 2007, Volume: 52, Issue:12 Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Blotting, Western; Collagen Type I; Disease Models, Animal; Disease Progression; Fatty Liver; Hypoglycemic Agents; Immunohistochemistry; Male; Pioglitazone; PPAR gamma; Rats; Rats, Inbred F344; Spectrophotometry; Telmisartan; Tetrazoles; Thiazolidinediones; Treatment Outcome; Valine; Valsartan	2007